<DOC>
	<DOCNO>NCT00866580</DOCNO>
	<brief_summary>This observer-blind study design evaluate immune response safety pandemic influenza vaccine elderly population .</brief_summary>
	<brief_title>A Study Evaluation GSK Biologicals ' Pandemic Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject age 61 year time first study visit ( Day 30 ) . Female subject nonchildbearing potential . Healthy subject subject well control chronic medical condition ( discretion investigator ) . Written inform consent obtain subject . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Subjects investigator believe comply requirement protocol enrol study . Previous administration license MF59containing vaccine , e.g . Fluad™ Addigrip™ virosomebased influenza vaccine Inflexal V™ , InfectoVac Flu™ Invivac™ . Previous administration 2009 Southern Hemisphere 20082009 Northern Hemisphere influenza vaccine . Previous administration pandemic influenza vaccine . Administration license vaccine within 4 week prior enrolment study . Planned administration vaccine foreseen study protocol 30 day second vaccination H5N1 vaccine . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first study vaccination . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History chronic alcohol consumption and/or drug abuse . History hypersensitivity vaccine . History reaction hypersensitivity likely exacerbate component vaccine . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Acute disease and/or fever time enrolment . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination.. Administration immunoglobulins and/or blood product within three month precede first study vaccination study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day prior first vaccination , plan use study period . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pandemic influenza</keyword>
</DOC>